Top Page
Hansa Biopharma AB
(HNSA)
Hansa Biopharma AB (HNSA) vs. iShares MSCI Sweden ETF (EWD)
Hansa Biopharma AB Business Overview & Revenue Model
Hansa Biopharma AB Earnings Call Summary
Hansa Biopharma AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 196.47M | 171.32M | 134.09M | 154.53M | 33.88M | 6.10M |
| Gross Profit | 132.81M | 87.76M | 70.95M | 116.05M | 18.45M | 5.10M |
| EBITDA | -458.73M | -642.07M | -714.55M | -554.26M | -538.83M | -413.08M |
| Net Income | -596.17M | -807.24M | -831.72M | -611.13M | -548.28M | -420.85M |
Balance Sheet | ||||||
| Total Assets | 837.27M | 800.64M | 1.02B | 1.69B | 1.01B | 1.43B |
| Cash, Cash Equivalents and Short-Term Investments | 354.42M | 405.28M | 732.06M | 1.50B | 888.96M | 1.38B |
| Total Debt | 906.21M | 1.08B | 866.77M | 791.09M | 35.38M | 5.04M |
| Total Liabilities | 1.28B | 1.39B | 1.19B | 1.08B | 255.24M | 192.37M |
| Stockholders Equity | -441.06M | -589.83M | -167.88M | 602.91M | 757.57M | 1.24B |
Cash Flow | ||||||
| Free Cash Flow | -619.84M | -675.00M | -755.94M | -506.06M | -483.57M | -290.57M |
| Operating Cash Flow | -619.21M | -674.88M | -755.65M | -502.73M | -481.17M | -290.27M |
| Investing Cash Flow | -628.00K | -116.00K | -284.00K | 229.31M | -2.40M | 182.53M |
| Financing Cash Flow | 270.50M | 346.81M | -7.54M | 1.12B | -4.86M | 1.07B |
Hansa Biopharma AB Technical Analysis
Hansa Biopharma AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | kr2.04B | 7.61 | 114.45% | ― | 1265.46% | ― | |
| ― | $1.83B | -6.27 | -36.52% | ― | 533.73% | 20.92% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | €1.09B | ― | -41.54% | ― | ― | 0.57% | |
| ― | kr2.63B | ― | -55.23% | ― | -92.57% | -7.72% | |
| ― | kr3.51B | -3.77 | ― | ― | 20.12% | 40.54% | |
| ― | kr592.94M | ― | -275.87% | ― | ― | 38.99% |
Hansa Biopharma AB Corporate Events
Hansa Biopharma’s recent earnings call presented a mixed sentiment, highlighting both achievements and challenges. The company celebrated a successful Phase 3 trial and sees promising opportunities in the U.S. market. However, it faces hurdles in Europe, particularly in Germany and Spain, with declining revenues. Despite these challenges, there is an improvement in the cash position and gross margin, though operating losses have increased.
Hansa Biopharma has increased its registered share capital and the number of shares and votes by issuing 17,000,000 new ordinary shares, bringing the total to 101,763,222 shares and votes. This move reflects the company’s strategic efforts to strengthen its financial position and support its ongoing research and development initiatives in the biopharmaceutical industry.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK32.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma announced that its drug imlifidase successfully met the primary endpoint in a pivotal U.S. Phase 3 trial for kidney transplantation, showing significant improvement in kidney function compared to the control group. The company plans to file a Biologic License Application with the FDA by the end of 2025, potentially enhancing its market position in the U.S. Additionally, Hansa reported a 25.4% increase in year-to-date product sales of IDEFIRIX, reflecting strong market performance. The company also completed a directed share issue raising approximately 671.5 MSEK to support its operational expansion and regulatory submissions.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK32.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma AB announced a virtual event featuring renowned transplant surgeons to discuss the clinical relevance of the US Phase 3 ConfIdeS study results on Imlifidase, a treatment for highly sensitized kidney transplant patients. This event underscores Hansa’s commitment to advancing transplantation medicine and highlights the potential impact of Imlifidase on improving transplant accessibility and outcomes for patients with limited donor options.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK32.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma is conducting a clinical study titled ‘A Prospective, Long-term Confirmatory Follow up Trial in Highly Sensitized Patients Treated With Imlifidase or Standard of Care in the ConfIdeS (20-HMedIdeS-17) Trial.’ The study aims to assess long-term patient survival and graft function in highly sensitized patients who have undergone desensitization treatment with imlifidase or standard care to facilitate kidney transplantation. This research is significant as it could improve outcomes for patients with limited transplant options.
Study Overview: The clinical study titled ‘An Open-Label, Systemic Gene Delivery Study to Evaluate the Safety, Tolerability and Expression of SRP-9001 in Association With Imlifidase in Subjects With Duchenne Muscular Dystrophy With Pre-existing Antibodies to rAAVrh74’ aims to assess the safety and efficacy of the gene therapy delandistrogene moxeparvovec (SRP-9001) when used alongside imlifidase. This study is significant as it targets Duchenne Muscular Dystrophy (DMD) patients who have pre-existing antibodies to the viral vector used in the therapy, potentially expanding treatment options for this group.
Hansa Biopharma is conducting a study titled A Prospective, Post-authorisation Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation, Including a Non-comparative Concurrent Reference Cohort. The study aims to assess the long-term efficacy and safety of imlifidase, an IgG-degrading enzyme, in patients who have undergone kidney transplantation. This research is significant as it could provide insights into the effectiveness of imlifidase in improving transplant outcomes.
Hansa Biopharma is conducting a clinical study titled ‘A Single-arm, Multi-centre Trial to Evaluate Efficacy and Safety of Imlifidase in Highly Sensitised Children (1-17 Years) Receiving a Kidney Transplant With Positive Crossmatch Against a Living or Deceased Donor Converted to Negative After Imlifidase Treatment’. The study aims to assess the efficacy and safety of imlifidase in enabling kidney transplantation in highly sensitized pediatric patients with end-stage renal disease. Key questions include whether imlifidase treatment can convert crossmatch results to negative and how well the transplanted kidney functions.
Hansa Biopharma and Genethon have announced successful results from a clinical trial using imlifidase as a pretreatment for gene therapy in a patient with Crigler-Najjar syndrome who is immune to AAV vectors. This breakthrough could potentially expand gene therapy options for patients previously ineligible due to immunity, marking a significant advancement in the treatment of rare genetic diseases.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma announced it will host a conference call to discuss its Q3 2025 interim results on October 30, 2025. The call, led by key executives, will cover the company’s financial performance and provide updates on its business and pipeline, reflecting its ongoing commitment to addressing serious medical needs in its field.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma announced that its CEO, Renée Aguiar-Lucander, will participate in two significant industry events: Optimum’s 17th Annual Healthcare Investor Conference and Nordic Life Science Days 2025. These engagements highlight Hansa’s active role in shaping industry discussions on exit strategies and future financing trends, potentially enhancing its visibility and influence in the biopharmaceutical sector.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma announced a directed share issue of 17 million ordinary shares to facilitate their trading on Nasdaq Stockholm, with trading expected to commence around October 6, 2025. This move is part of Hansa’s strategic efforts to enhance its market presence and operational capabilities, potentially impacting its industry positioning and stakeholder interests.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma has successfully raised approximately USD 71 million through a directed share issue of 17 million shares, aimed at Swedish and international institutional investors. The proceeds will support the company’s strategic initiatives, including a potential Biologic License Application filing with the FDA for imlifidase, and enhancing its medical and commercial capabilities in the U.S. This capital raise is a strategic move to strengthen Hansa’s market position and prepare for the potential U.S. launch of imlifidase, reflecting strong investor confidence and expanding its shareholder base.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma AB announced its intention to raise approximately USD 60 million through a directed share issue aimed at Swedish and international institutional investors. The funds will support the company’s strategic initiatives, including the potential filing of a Biologic License Application with the FDA and preparations for the commercial launch of imlifidase in the U.S. The decision for a directed share issue, as opposed to a rights issue, was made to ensure timely capital acquisition and to attract strategic biotechnology investors, reflecting the company’s proactive approach to strengthening its market position.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma announced that Genethon will present preliminary data from a Phase 2 trial of imlifidase as a pre-treatment for gene therapy in patients with severe Crigler-Najjar syndrome at the ESGCT congress. The trial, which aims to address the barrier of anti-AAV antibodies in gene therapy, could significantly impact the treatment landscape for this ultra-rare disease, potentially enabling more patients to benefit from gene therapies.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma announced successful results from its US Phase 3 ConfIdeS trial for imlifidase, showing significant improvement in kidney function in highly sensitized transplant patients. The positive outcomes, including superior kidney function and dialysis independence, position imlifidase as a potential transformative treatment in kidney transplantation, with plans for a Biologic License Application submission to the FDA by the end of 2025.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma announced that its CEO, Renée Aguiar-Lucander, will present at the 16th Annual Pareto Securities Healthcare Conference in Stockholm. The presentation and subsequent panel discussion will address current industry dynamics, including business deals, healthcare system changes, and investor sentiment, potentially impacting the company’s operations and positioning within the biopharmaceutical industry.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK33.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, where CEO Renée Aguiar-Lucander will engage in a Fireside chat. This participation highlights Hansa’s ongoing efforts to engage with investors and stakeholders, potentially impacting its industry positioning by showcasing its innovative treatments and strategic direction.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK33.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma AB held an Extraordinary General Meeting where it resolved to maintain the number of Board members at eight and elected Elisabeth Björk, Natalie Berner, and Michael Bologna as new members. The meeting also confirmed that the Board’s fees would remain unchanged, although Berner and Bologna declined remuneration. These changes in the Board composition could impact the company’s strategic direction and governance.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK33.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma AB has announced an Extraordinary General Meeting scheduled for September 2, 2025, to discuss several key resolutions, including the election of new members to the Board of Directors. The Nomination Committee has proposed the election of Elisabeth Björk, Natalie Berner, and Michael Bologna as new board members, with remuneration details outlined for various committee roles. This meeting is significant for the company’s governance structure, potentially impacting its strategic direction and stakeholder engagement.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
Hansa Biopharma has announced promising results from a trial involving the use of imlifidase in patients with Duchenne muscular dystrophy (DMD) prior to gene therapy. The trial showed that imlifidase effectively reduced IgG antibodies, allowing patients to receive Sarepta’s gene therapy, ELEVIDYS. This development could potentially enhance access to gene therapy for patients with high levels of anti-AAV antibodies, positioning Hansa Biopharma as a key player in addressing barriers to gene therapy in rare diseases.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.